IJGC Podcast

By BMJ GroupMedicine Health & Fitness

IJGC Podcast episodes

April 14, 2021 Legends in Gynecologic Oncology with Charles Levenback
In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Dr. Charles Levenback, who is being highlighted by IJGC as a legend in gynecologic oncology. Dr. Levenback completed his fellowship at Memorial Sloan Kettering Cancer center in 1989 and then practiced at MD Anderson for 31 years. He is known as a pioneer in the development of sentinel lymph node biopsy in Gynecologic oncology, master clinician, educator, and champion for quality and safety.
Highlights:
+ Career and professional development
+ Sentinel lymph node development from small case series to phase III national trial
+ Interest in quality improvement and patient safety
41 min
April 13, 2021 Reviewing the April Issue with Enrique Chacon (Spanish Version)
In this episode of the IJGC Podcast, Editorial Fellow Enrique Chacon discusses the contents of the April issue in Spanish.
19 min
April 12, 2021 The Mentors Podcast with Pedro Ramirez
In this episode of the IJGC Podcast, Editor-in-Chief Pedro Ramirez joins Editorial Fellows Anna Collins, Irina Tsibulak, Nicolò Bizzarri, Alex Mutombo, Enrique Chacon and Arthur Hsu for an extended discussion of their experiences in gynecologic oncology, the importance of mentorship, and pathways for development in the field.
40 min
April 07, 2021 ERAS Impact on Return to Treatment in Ovarian Cancer with Kevin Elias
In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Dr. Kevin Elias to discuss the ERAS impact on return to treatment in ovarian cancer. Kevin Elias is an Assistant Professor of Gynecologic Oncology and Director of the Gynecologic Oncology Laboratory at Brigham and Women’s Hospital, Dana-Farber Cancer Institute, and Harvard Medical School. He is the President-Elect of ERAS USA, the American chapter of the ERAS Society.
Highlights
A. ERAS is associated with shorter lengths of stay and fewer complications for patients undergoing cytoreductive surgery.
B. The benefits of ERAS seem to extend beyond the hospital stay, as ERAS is strongly associated with timely resumption of adjuvant chemotherapy.
C. Auditing ERAS compliance is a key part of implementing an ERAS pathtway.
D. ERAS reduces variation in the quality of patient care, which improves consistency in oncologic treatments and potentially outcomes.
32 min
March 31, 2021 Reviewing the April Issue with Irina Tsibulak (Russian Version)
In this episode of the IJGC Podcast, Editorial Fellow Irina Tsibulak discusses the contents of the April issue in Russian.
13 min
March 31, 2021 Reviewing the April Issue with Anna Collins and Irina Tsibulak (English Version)
In this episode of the IJGC Podcast, Editorial Fellows Anna Collins and Irina Tsibulak discuss the contents of the April issue.
14 min
March 29, 2021 Radical Hysterectomy in Cervical Neuroendocrine Carcinoma with Michael Frumovitz
In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Dr. Michael Frumovitz to discuss radical hysterectomy in cervical neuroendocrine carcinoma. Dr. Frumovitz is an Associate Editor for IJGC and the author of the Lead Article of the April 2021 issue of IJGC, “Role of radical hysterectomy in patients with early-stage high-grade neuroendocrine cervical carcinoma: a NeCTuR study" (https://ijgc.bmj.com/content/early/2021/03/09/ijgc-2020-002213).
Highlights:
1. Patients with clinical and radiologic stage I high grade neuroendocrine carcinoma of the cervix will have microscopic parametrial involvement 10% of the time
2. All patients with parametrial involvement will have other risk factors requiring postoperative radiation (positive nodes or Sedlis)
3. If a patient has negative nodes, the risk of parametrial involvement is only 3%
4. Eighty percent of recurrences will happen within first two years and 86% destined to recur will recur within 3 years
35 min
March 23, 2021 IDEAL Framework Surgical Research Trials with Peter McCulloch
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Peter McCulloch to discuss the IDEAL Framework. Dr. McCulloch is Professor of Surgical Science & Practice at Oxford University. He attended medical school in Aberdeen and underwent his surgical training in Glasgow before moving to academic posts in Liverpool and then Oxford. An Upper GI cancer surgeon by background, he is the Chair of the IDEAL Collaboration, an international network of surgeons, scientists, industrial partners and patients whose goal is to improve the methodology for evaluating surgery, therapeutic devices and other complex treatments. He is also the Co-Editor-in-Chief of BMJ Surgery, Interventions, & Health Technologies (sit.bmj.com). His other major research interest is Human Factors in healthcare. He will ski anywhere, anytime, and is passionate about countering climate change.
Highlights:
• The IDEAL Framework & Recommendations provide an explanation of the natural history or life cycle of new procedures and devices, and a road map for how they should be evaluated at each stage in the journey.
• It explains why Randomised Trials have been so difficult to do in surgery and shows that there are at least 2 preliminary steps in research (Development and Exploration) which are necessary to ensure that an RCT has a good chance of success.
• IDEAL is potentially useful in surgical research at all stages, but also in device regulatory science, decisions on approving new procedures at institutions and coverage decisions
• IDEAL is increasingly recognised and endorsed by major journals (Annals of Surgery, BMJ & Lancet) and professional groups (Royal College of Surgeons) and is being used by government agencies in several countries.
• The IDEAL group continues to study and produce recommendations on difficult research issues such as: When is it OK NOT to do a randomised trial? How do we interpret studies using Real World Data? How should surgical robots be evaluated? And others.
48 min
March 18, 2021 MITO16b Trial: Bevacizumab in Platinum-Sensitive Ovarian Cancer with Sandro Pignata
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Sandro Pignata to discuss the MITO16b trial. Dr. Pignata is president of the Multicenter Italian Trial in Ovarian cancer (MITO) group, member of the educational committee of ESMO, Past Chair of the European Network of Gynaecological Oncological Trial Groups (ENGOT), and member of the board of directors of the Gynecologic Cancer InterGroup (GCIG).
Highlights:
- The paper published on the Lancet demonstrate that bevacizumab given at recurrence is effective also in patients already treated with bevacizumab in first line.
- Exploratory analysis suggest that this effect is not present in BRCA mutated patients.
28 min
March 12, 2021 Reviewing the March Issue with Alex Mutombo (French Version)
In this episode of the IJGC Podcast, Editorial Fellow Alex Mutombo reviews the contents of the March issue in French.
15 min

About IJGC Podcast

From the publisher's feed

The International Journal of Gynecological Cancer (IJGC) podcast explores the latest research on detection, prevention, diagnosis, and treatment of gynecologic malignancies. Enjoy interviews with leading experts as they discuss novel and relevant topics in the field of gynecologic cancer.